Synairgen plc Phase II Biomarker Data for SNG001 to be presented
27 Settembre 2019 - 8:01AM
RNS Non-Regulatory
TIDMSNG
Synairgen plc
27 September 2019
RNS REACH
Press release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen to Present Phase II Biomarker Data for SNG001 at the
European Respiratory Society International Congress
Southampton, UK - 27 September 2019: Synairgen (LSE: SNG), the
respiratory drug discovery and development company, is presenting
biomarker data from the first part of its ongoing Phase II trial of
its wholly-owned antiviral therapy inhaled interferon beta
(IFN-beta) in patients suffering from chronic obstructive pulmonary
disease (COPD), at the European Respiratory Society (ERS)
International Congress being held in Madrid 28 September - 2
October 2019.
Exacerbations of COPD are associated with disease progression
and are a major cause of the healthcare burden associated with this
common disease. A significant proportion of exacerbations are
caused by respiratory viruses, such as those that cause the common
cold and flu, when infections spread to the lungs.
Synairgen's two-part Phase II trial, called SG015, has been
designed to assess Synairgen's inhaled IFN-beta in COPD patients
when they have a cold or flu infection. The data being presented
are from Part 1 of the study, in which patients were treated with
inhaled IFN-beta when they did not have a cold or flu infection.
Analysis of samples from the lung shows that treatment with
IFN-beta boosted the lungs' antiviral defences, increasing
Synairgen's confidence in the likelihood of a positive outcome in
Part 2 of the study in which inhaled IFN-beta is being assessed
when patients do have a confirmed respiratory virus infection.
The data will be presented by Synairgen's Chief Scientific
Officer, Dr Phillip Monk, at the Congress on Sunday 29 September in
the session entitled "COPD clinical trials: new molecules and novel
insights" (8.30 to 10.30 am Room 6F).
Professor Tom Wilkinson, leading international lung disease
specialist and Chief Investigator for the SG015 study, commented:
"Respiratory virus infections, such as the common cold and flu, are
a major cause of exacerbations of COPD, which are the second most
common cause of unplanned hospital admission in England, so there
is a real need for a treatment that helps patients when they have a
cold or flu infection. The biomarker data from Part 1 indicate that
we are 'switching on' antiviral defences in the lungs which we hope
will translate into a clinical benefit in Part 2 of the study, when
patients take either placebo or inhaled IFN-beta for 14 days when
they have a confirmed respiratory viral infection. The trial is
progressing well, and we are on track to complete the study during
this coming winter virus season."
- Ends -
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Alice Lane (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease.
Synairgen is currently running a two-part Phase II trial
evaluating SNG001, the Company's wholly-owned inhaled interferon
beta (IFN-beta) therapeutic candidate. The Phase II trial, called
SG015, has been designed to assess the safety of SNG001 in COPD
patients and its clinical benefit in these patients when they have
a cold or flu infection, a major driver of COPD exacerbations.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASEWESMFUSELU
(END) Dow Jones Newswires
September 27, 2019 02:01 ET (06:01 GMT)
Grafico Azioni Synairgen (LSE:SNG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Synairgen (LSE:SNG)
Storico
Da Apr 2023 a Apr 2024